These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 11794976

  • 1. [Venous thromboembolic pathology. New acquired risk factors or new data on acquired risk factors].
    Drouet L.
    Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1318-26. PubMed ID: 11794976
    [Abstract] [Full Text] [Related]

  • 2. Genetic risk factors of venous thrombosis.
    Franco RF, Reitsma PH.
    Hum Genet; 2001 Oct; 109(4):369-84. PubMed ID: 11702218
    [Abstract] [Full Text] [Related]

  • 3. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J.
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [Abstract] [Full Text] [Related]

  • 4. Classical risk factors and emerging elements in the risk profile for coronary artery disease.
    Gensini GF, Comeglio M, Colella A.
    Eur Heart J; 1998 Feb; 19 Suppl A():A53-61. PubMed ID: 9519344
    [Abstract] [Full Text] [Related]

  • 5. [Vascular placental pathology in high-risk groups: definition and synopsis].
    Foidart JM, Seak-San S, Emonts P, Schaaps JP.
    Ann Med Interne (Paris); 2003 Feb; 154(5-6):332-9. PubMed ID: 15027587
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies.
    Chopra N, Koren S, Greer WL, Fortin PR, Rauch J, Fortin I, Senécal JL, Docherty P, Hanly JG.
    J Rheumatol; 2002 Aug; 29(8):1683-8. PubMed ID: 12180730
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for venous thromboembolism in children.
    Gerotziafas GT.
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [Abstract] [Full Text] [Related]

  • 9. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA.
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [Abstract] [Full Text] [Related]

  • 10. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
    Miñano A, Ordóñez A, España F, González-Porras JR, Lecumberri R, Fontcuberta J, Llamas P, Marín F, Estellés A, Alberca I, Vicente V, Corral J.
    Haematologica; 2008 May; 93(5):729-34. PubMed ID: 18387978
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of thrombotic children with malignancy.
    Unal S, Varan A, Yalçin B, Büyükpamukçu M, Gürgey A.
    Ann Hematol; 2005 Jun; 84(6):395-9. PubMed ID: 15735962
    [Abstract] [Full Text] [Related]

  • 12. [Epidemiology and etiopathogenesis of deep venous thrombosis of the lower limbs].
    Bounameaux H.
    Agressologie; 1990 Mar; 31(3):141-3. PubMed ID: 2240406
    [Abstract] [Full Text] [Related]

  • 13. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N.
    J Natl Cancer Inst; 2006 Jul 05; 98(13):904-10. PubMed ID: 16818854
    [Abstract] [Full Text] [Related]

  • 14. [Venous thromboembolic disease: which coagulation screening, for whom, when?].
    Wautrecht JC.
    Rev Med Brux; 2005 Sep 05; 26(4):S315-9. PubMed ID: 16240880
    [Abstract] [Full Text] [Related]

  • 15. [Combined contraceptives and cardiovascular risk].
    Belaisch J, Hommais-loufrani B.
    Contracept Fertil Sex (Paris); 1987 Dec 05; 15(12 Suppl):1-8. PubMed ID: 12315199
    [Abstract] [Full Text] [Related]

  • 16. [Hormone replacement therapy and venous thromboembolism].
    Trillot N, Susen S, Jude B.
    Gynecol Obstet Fertil; 2004 Sep 05; 32(9):725-8. PubMed ID: 15380753
    [Abstract] [Full Text] [Related]

  • 17. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A, de Azevedo MN, de Souza Papi JA, Petri M.
    J Rheumatol; 2009 Jun 05; 36(6):1195-9. PubMed ID: 19447935
    [Abstract] [Full Text] [Related]

  • 18. Blood viscosity and thrombosis: clinical considerations.
    Smith BD, La Celle PL.
    Prog Hemost Thromb; 1982 Jun 05; 6():179-201. PubMed ID: 6762612
    [Abstract] [Full Text] [Related]

  • 19. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
    Libourel EJ, Bank I, Meinardi JR, Baljé -Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, van Pampus EC, Prins MH, Büller HR, van der Meer J.
    Haematologica; 2002 Oct 05; 87(10):1068-73. PubMed ID: 12368162
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb 05; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.